A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
Clinical trial NCT07245797 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07245797
- Sponsor
- Zhimin Shao
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-15
- Primary completion
- 2026-12-15
- Enrollment
- 164
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.